DOCSLIB.ORG

ZINF Bericht 1 General Remarks & Teaser Final 08 Dec 2020.Indd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ZINF Bericht 1 General Remarks & Teaser Final 08 Dec 2020.Indd SCIENTIFIC REPORT 2018-2019 RESEARCH CENTER FOR INFECTIOUS DISEASES (ZINF) ZINF NUMBERS ABOUT THE ZINF 2018-2019 The Research Center for Infectious Diseases (ZINF) is a MULTI-DISCIPLINARY NETWORK of researchers in Würzburg addressing molecular principles of host-pathogen interactions. It brings together experts from MICROBIOLOGY, PARASITOLOGY, VIROLOGY, IMMUNOLOGY, CHEMISTRY, and CLINICAL PRACTICE and facilitates cross-faculty communication, initiation of joint research activities, as well as recruitment of extramural funding. -V\UKLKPU ^P[OÄUHUJPHSZ\WWVY[MYVT[OL-LKLYHS4PUPZ[Y`VM9LZLHYJOHUK ;LJOUVSVN`HUK HM[LY^HYKZ [OL )H]HYPHU :[H[L 4PUPZ[Y` MVY 9LZLHYJO HUK (Y[ [OL ZINF represents the OLDEST ACADEMIC INSTITUTION in Germany devoted to interdisciplinary research on infectious diseases. With 35 professors in infection biology, infectious diseases research is a key area of biomedical research at the Julius 4H_PTPSPHUZ <UP]LYZP[` VM > YaI\YN 14< ;OL A05- NYLH[S` ILULÄ[Z MYVT Z[YVUN PU[LYHJ[PVUZHJYVZZMHJ\S[PLZJSPUPJZHUKYLZLHYJOPUZ[P[\[PVUZV\[ZPKL[OL14< ( JVYL JVTWVULU[ VM [OL A05- OHZ ILLU P[Z YOUNG INVESTIGATOR GROUP WYVNYHT [OH[ VќLYZ H \UPX\L LU[Y` MVY `V\UN YLZLHYJOLYZ PU[V [OLPY V^U ZJPLU[PÄJ career. Research of the independent ZINF junior groups covered in the period of this report focuses on organoids as new infection models, high-throughput technologies [VZ[\K`[OLTVKLVMHJ[PVUVMHU[PIPV[PJJVTIPUH[PVUZYLN\SH[VY`95(TVSLJ\SLZPU anaerobic pathogens and in the microbiome, structural biology of mycobacteria, as well as the role of the microbiota in fungal infections. ;OLA05-PZHJLU[YHSZJPLU[PÄJMHJPSP[`VM[OL14<> YaI\YNHUKOHZL]VS]LKPU[VHU internationally recognized and accredited institution. 2 3 3.5 DEPARTMENT OF MICROBIOLOGY, THEODOR BOVERI INSTITUTE, BIOCENTER 64 CONTENT Thomas Rudel - Infection Biology of Bacteria 66 4HY[PU-YH\UOVSa*LSS\SHY4PJYVIPVSVN` 9V`.YVZZ7LY[\ZZPZ ZINF SCIENTIFIC REPORT 2018-2019 Vera Kozjak-Pavlovic - Bacterial Invasion and Intracellular Survival 69 3.6 DEPARTMENT OF INTERNAL MEDICINE II 70 1. GENERAL REMARKS Hermann Einsele - Interaction of Aspergillus fumigatus ^P[O/\THU5H[\YHS2PSSLY*LSSZHUK+LUKYP[PJ*LSSZ (UKYLHZ)LPSOHJR,_WLYPTLU[HS:[LT*LSS;YHUZWSHU[H[PVU 1.1 Speaker‘s Report / Bericht der Sprecherin 10 /HY[^PN2SPURLY+P]PZPVUVM0UMLJ[PV\Z+PZLHZLZ 1.2 Structure of the ZINF 14 1 YNLU3ўLY0TT\UP[`HNHPUZ[AspergillusZWW 1.3 Events surrounding the ZINF 16 3.7 INSTITUTE OF SYSTEMS IMMUNOLOGY 76 2. YOUNG INVESTIGATOR GROUPS OF THE ZINF .LVYN.HZ[LPNLY;PZZ\L0TT\UP[` 4LYJLKLZ.VTLaKL(N LYV/VZ[4PJYVIPHS0U[LYHJ[PVUZ :PUH)HY[MLSK6YNHUVPKZHZ/VZ[4VKLSZ 4HY[PU=HL[O4L[HIVSPZTHUK0TT\UL*LSS:PNUHSSPUN (UH9P[H)YVJOHKV:`Z[LTZ)PVSVN`VM(U[PIPV[PJ(J[PVU -YHUaPZRH-HILY95()PVSVN`VM*SVZ[YPKPVPKLZKPѝJPSL :LIHZ[PHU.LPILS:[Y\J[\YHS)PVSVN`VM4`JVIHJ[LYPH 3.8 HELMHOLTZ INSTITUTE FOR RNA-BASED INFECTION RESEARCH 82 Christian Perez - Regulatory Networks in Pathogenesis 30 3HYZ)HYX\PZ[0U[LNYH[P]L0UMVYTH[PJZMVY0UMLJ[PVU)PVSVN` *OHZL)LPZLS95(:`U[OL[PJ)PVSVN` 5L]H*HSPZRHU9LJVKPUN4LJOHUPZTZPU0UMLJ[PVUZ 4H[OPHZ4\UZJOH\LY+LJVKPUN95(7YV[LPU0U[LYHJ[VTLZVM9LN\SH[VY`95(PU0UMLJ[PVU 3. MEMBERS OF THE ZINF (U[VPUL,TTHU\LS:HSPIH:PUNSLJLSS(UHS`ZPZ 3.1 INSTITUTE OF MOLECULAR INFECTION BIOLOGY 34 9LKTVUK:T`[O.LUVTL(YJOP[LJ[\YLHUK,]VS\[PVUVM95(=PY\ZLZ 1YN=VNLS95()PVSVN` *`U[OPH:OHYTH+LLW:LX\LUJPUN(WWYVHJOLZ[V7H[OVNLULZPZ 3.9 ZINF MEMBER ASSOCIATED WITH OTHER INSTITUTES 90 /LPKY\U4VSS0UMLJ[PVU0TT\UVSVN` ;OVTHZ+HUKLRHY)PVPUMVYTH[PJZ 1VHJOPT4VYZJOOp\ZLY4`JVSVN` 4HYR\Z,UNZ[SLY4VSLJ\SHYHUK7O`ZPJHS7HYHZP[VSVN` Knut Ohlsen - Gram-positive Cocci 40 <SYPRL/VSaNYHIL4LKPJPUHS*OLTPZ[Y` (SL_HUKLY>LZ[LYTHUU/VZ[7H[OVNLU4PJYVIPV[H0U[LYHJ[PVUZ Caroline Kisker - Structure-based Drug Design 95 >PSTHAPLI\OY5VZVJVTPHS0UMLJ[PVUZI`:[HWO`SVJVJJP 4HYJV4L[aNLY/\THU+;PZZ\L4VKLSZ[V:[\K`/VZ[7H[OVNLU0U[LYHJ[PVUZPU0UMLJ[PV\Z9LZLHYJO 1 YNLU:LPILS*OLTPZ[Y`VM3P]PUN:`Z[LTZ (\N\Z[:[PJO;YVWPJHS4LKPJPUL 3.2 INSTITUTE FOR HYGIENE AND MICROBIOLOGY 44 4H[[OPHZ-YVZJO4VSLJ\SHY:\Y]LPSSHUJLVM0U]HZP]L)HJ[LYPHS0UMLJ[PVUZ 6SP]LY2\YaHP4LKPJHS4PJYVIPVSVN`HUK4`JVSVN` 2SH\Z)YLOT/LSTPU[O0UMLJ[PVUZ 4. RESEARCH PROGRAMS *OYPZ[VWO:JOVLU4VSLJ\SHY+PHNUVZ[PJZHUK-\UJ[PVUHS.LUVTPJZVM/\THU7H[OVNLUPJ)HJ[LYPH +-.*VSSHIVYH[P]L9LZLHYJO*LU[LY*9*:-);YHUZYLNPV (SL_HUKYH:JO\ILY[<URTLPY/VZ[7H[OVNLU0U[LYHJ[PVUZ 4.1 +-.*VSSHIVYH[P]L9LZLHYJO*LU[LY*9*:-);YHUZYLNPV <SYPJO=VNLS0UMLJ[PVU,WPKLTPVSVN`VMNeisseria meningitidis and Hospital Infection Control 51 4.2 4.3 +-.9LZLHYJO<UP[ 4.4 +-.9LZLHYJO<UP[ 3.3 INSTITUTE FOR VIROLOGY AND IMMUNOBIOLOGY – DEPARTMENT OF VIROLOGY 52 4.5 +-.9LZLHYJO<UP[ Lars Dölken - Systems Biology of Herpesvirus Infections 54 4.6 +-.7YPVYP[`7YVNYHT:77 Florian Erhard - Computational Systems Virology 55 4.7 DFG Priority Program SPP 1656 105 1 YNLU:JOULPKLY:JOH\SPLZ4VYIPSSP]PY\Z7H[OVNLULZPZ 4.8 +-.7YPVYP[`7YVNYHT:77 :PI`SSL:JOULPKLY:JOH\SPLZ=PYHS0TT\UVTVK\SH[PVU 4.9 +-.7YPVYP[`7YVNYHT:77 4.10 +-.7YPVYP[`7YVNYHT:77 4.11 +-.7YPVYP[`7YVNYHT:77 3.4 INSTITUTE FOR VIROLOGY AND IMMUNOBIOLOGY – DEPARTMENT OF IMMUNOLOGY 58 4.12 +-.7YPVYP[`7YVNYHT:77 Wolfgang Kastenmüller - Leukocyte Dynamics 60 4.13 +-..LYTHU(MYPJHU*VVWLYH[PVU7YVQLJ[ZPU0UMLJ[PVSVN` Niklas Beyersdorf - T Cell Biology 61 4.14 )4)- /LHS[O7YL]LU[ ;OVTHZ/LYYTHUU0TT\UVNLUL[PJZ 4.15 )4)-0UMLJ[*VU[YVS 4HUMYLK3\[a0TT\UL9LN\SH[PVU 4.16 )4)-;HYNL[=HSPKH[PVUMVY7OHYTHJL\[PJHS+Y\N+L]LSVWTLU[ 4.17 )4)-P407 4 5 4. RESEARCH PROGRAMS 4.18 ,\YVWLHU9LZLHYJO(YLH5L[^VYRZ,9(5L[ 4.19 International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) 113 4.20 0)+3HIUL[*VVYKPUH[PVUVM(J[P]P[PLZMVY3HIVYH[VY`:\Y]LPSSHUJLVM0U]HZP]L)HJ[LYPHS+PZLHZLZ 4.21 >LSSJVTL;Y\Z[:[YH[LNPJ(^HYK 4.22 ,SZL2YULY*LU[LYMVY(K]HUJLK4LKPJHS 4LKPJHS/\THUP[HYPHU:[\KPLZ> YaI\YN¶4^HUaH;HUaHUPH 4.23 )H]HYPHU9LZLHYJO5L[^VYRIH`YLZXUL[ 5. INFRASTRUCTURE 5.1 593MVY4LUPUNVJVJJPHUK/HLTVWOPS\ZPUÅ\LUaHL 5.2 ;OL*VUZ\S[PUN3HIVYH[VY`MVY,JOPUVJVJJVZPZ 5.3 German Center for Infection Research (DZIF) 119 5.4 Interdisciplinary Center for Clinical Research (IZKF) 119 5.5 *VYL<UP[:`Z[LTZ4LKPJPUL 6. TRAINING THE NEXT GENERATION 6.1 .YHK\H[L:JOVVSVM3PML:JPLUJLZ.:3: 6.2 +-.9LZLHYJO;YHPUPUN.YV\W.YHK\PLY[LURVSSLN.92+0UMLJ[ 6.3 +-.9LZLHYJO;YHPUPUN.YV\W.YHK\PLY[LURVSSLN.92<)0 6.4 +-.9LZLHYJO;YHPUPUN.YV\W.YHK\PLY[LURVSSLN.92:7/05.605- 7. APPENDIX 7.1 A05-@V\UN0U]LZ[PNH[VY.YV\W3LHKLYZ(S\TUP 7. 2 4LL[PUNZHUK>VYRZOVWZJVVYNHUPaLKI`A05-4LTILYZ 7. 3 :LTPUHYZHUK*VSSVX\PH 7. 4 Funding 140 7. 5 7\ISPJH[PVUZ 7. 6 +PYLJ[VY`VM7LVWSL(ZZVJPH[LK^P[O[OLA05- 6 7 1.1 GENERAL REMARKS 1 GENERAL REMARKS 8 9 *'*LI>:D>KLK>IHKM genome architecture and its impact on antigenic variation JVUZVY[P\T1YN=VNLS-YHUaPZRH-HILYHUK3HYZ)HYX\PZ[ *'*LI>:D>KLK>IHKM of trypanosomes, which was performed by his group in KL]LSVWUL^WYVNYHTTHISL95(IHZLKHU[PIPV[PJZHNHPUZ[ > YaI\YN ;OPZ Z[\K` HSZV PUJS\KLK [OL ÄYZ[ ZJ95(ZLX T\S[PYLZPZ[HU[WH[OVNLUZ(UH9P[H)YVJOHKVHUKT`ZLSM analysis of trypanosomes, which his lab set up jointly with [VNL[OLY ^P[O *OYPZ[PHU 4 SSLY 4\UPJO ^PSS LTWSV` OPNO 2018-2019 [OL:HSPIHNYV\W0U [OLNYV\WVM:LIHZ[PHU.LPILS throughput approaches to decipher stress pathways reported the cryo-electron microscopy resolution of the involved in antibiotics resistance and virulence of pathogens structure of the core complex of the type VII secretion in our StressRegNet consortium. Dear readers, system from mycobacteria in Nature. The success of the Besides the organization of several conferences A05-PZHSZVYLÅLJ[LKI`WYVMLZZVYZOPWVќLYZ[VJ\YYLU[A05- and symposia by ZINF members, we were happy to Infectious diseases remain one of the central challenges for VM [OL :(9:*V= 95( HUK [OL O\THU OVZ[ WYV[LVTL @0.SLHKLYZHUKI`[OLA05-@0.(S\TUPOVSKPUNUH[PVUHS welcome many international scientists and guest speakers ZJPLUJLHUKTLKPJPULPU[OLst century. The ongoing global (5H[\YL 4PJYVIPVSVN` PU WYLZZ >P[OPU [OL .92 + or international professorships or group leader positions. H[V\YJVSSVX\PHHUKZLTPUHYZLYPLZPU> YaI\YNW :(9:*V= WHUKLTPJ OHZ JSLHYS` ZOV^U [OH[ [OL ÄNO[ 0UMLJ[UL^WYVQLJ[ZVU:(9:*V=OH]LILLUSH\UJOLK 4VZ[YLJLU[S`^LJVUNYH[\SH[L:PUH)HY[MLSKVUHUVќLYMVY ,HYSPLY PU [OL -HJ\S[` VM )PVSVN` H^HYKLK HU against infectious diseases is of particular social, political, and, together with the lab of Chase Beisel, my group has a Full Professor (W3) position as well as Christian Pérez on honorary doctorate to the renowned infection biologist and and economic importance. The global challenges of a been developing a CRISPR/Cas-based diagnostic method OPZUL^WVZP[PVUHZ(ZZVJPH[L7YVMLZZVYH[<;/LHS[OHUK vaccinologist Rino Rappuoli (Siena). Peter Fineran from the rising threat of zoonotic pathogens such as coronaviruses [OH[ JHU KPZ[PUN\PZO KPќLYLU[ YLZWPYH[VY` ]PY\ZLZ PUJS\KPUN wish him a great start in Houston. <UP]LYZP[` VM 6[HNV PU 5L^ ALHSHUK YLJLP]LK H 9LZLHYJO or emerging antimicrobial resistances that threaten the :(9:*V= :\WWVY[LK I` HU PU[LYUH[PVUHS ZJPLU[PÄJ HK]PZVY` -LSSV^ZOPWMVY,_WLYPLUJLK9LZLHYJOLYZMYVT[OL(SL_HUKLY LќLJ[P]L [YLH[TLU[ VM PUMLJ[PVUZ YLX\PYL H JVSSLJ[P]L LќVY[ With the establishment of the ZINF in 1993 by Volker IVHYK:()VMSLHKPUNZJPLU[PZ[Z[OLA05-OHZL]VS]LKPU[V von Humboldt Foundation to visit the labs of Chase Beisel of scientists from all disciplines, developing and integrating [LY4L\SLU>LYULY.VLILSHUKJVSSLHN\LZHUKZ\WWVY[LK an internationally recognized and accredited institution. We HUKTPULPU >LSVVRMVY^HYK[VOVZ[PUNOPTHNHPUPU new technologies and innovative strategies to study I` [OL -LKLYHS 4PUPZ[Y` VM 9LZLHYJO HUK ;LJOUVSVN`HUK would like to express our deepest gratitude to the members [VJVU[PU\LV\YQVPU[^VYRVU[OLYLN\SH[PVUVM infection processes and develop novel therapeutics and afterwards the Bavarian Government, Würzburg gained VMV\Y:()HUK^LYLKLSPNO[LK[V^LSJVTL4LSHUPL)SVRLZJO bacterial CRISPR-Cas immune systems.
Load more

Recommended publications
  • Ubiquitination, Ubiquitin-Like Modifiers, and Deubiquitination in Viral Infection
    Ubiquitination, Ubiquitin-like Modifiers, and Deubiquitination in Viral Infection The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Isaacson, Marisa K., and Hidde L. Ploegh. “Ubiquitination, Ubiquitin- like Modifiers, and Deubiquitination in Viral Infection.” Cell Host & Microbe 5, no. 6 (June 2009): 559-570. Copyright © 2009 Elsevier Inc. As Published http://dx.doi.org/10.1016/j.chom.2009.05.012 Publisher Elsevier Version Final published version Citable link http://hdl.handle.net/1721.1/84989 Terms of Use Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. Cell Host & Microbe Review Ubiquitination, Ubiquitin-like Modifiers, and Deubiquitination in Viral Infection Marisa K. Isaacson1 and Hidde L. Ploegh1,* 1Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA *Correspondence: [email protected] DOI 10.1016/j.chom.2009.05.012 Ubiquitin is important for nearly every aspect of cellular physiology. All viruses rely extensively on host machinery for replication; therefore, it is not surprising that viruses connect to the ubiquitin pathway at many levels. Viral involvement with ubiquitin occurs either adventitiously because of the unavoidable usur- pation of cellular processes, or for some specific purpose selected for by the virus to enhance viral replica- tion. Here, we review current knowledge of how the ubiquitin pathway alters viral replication and how viruses influence the ubiquitin pathway to enhance their own replication. Introduction own ubiquitin ligases or ubiquitin-specific proteases, it seems Ubiquitin is a small 76 amino acid protein widely expressed in reasonable to infer functional relevance, but even in these cases, eukaryotic cells.
    [Show full text]
  • Challenges and Approaches for the Development of Safer Immunomodulatory Biologics
    REVIEWS Challenges and approaches for the development of safer immunomodulatory biologics Jean G. Sathish1*, Swaminathan Sethu1*, Marie-Christine Bielsky2, Lolke de Haan3, Neil S. French1, Karthik Govindappa1, James Green4, Christopher E. M. Griffiths5, Stephen Holgate6, David Jones2, Ian Kimber7, Jonathan Moggs8, Dean J. Naisbitt1, Munir Pirmohamed1, Gabriele Reichmann9, Jennifer Sims10, Meena Subramanyam11, Marque D. Todd12, Jan Willem Van Der Laan13, Richard J. Weaver14 and B. Kevin Park1 Abstract | Immunomodulatory biologics, which render their therapeutic effects by modulating or harnessing immune responses, have proven their therapeutic utility in several complex conditions including cancer and autoimmune diseases. However, unwanted adverse reactions — including serious infections, malignancy, cytokine release syndrome, anaphylaxis and hypersensitivity as well as immunogenicity — pose a challenge to the development of new (and safer) immunomodulatory biologics. In this article, we assess the safety issues associated with immunomodulatory biologics and discuss the current approaches for predicting and mitigating adverse reactions associated with their use. We also outline how these approaches can inform the development of safer immunomodulatory biologics. Immunomodulatory Biologics currently represent more than 30% of licensed The high specificity of the interactions of immu- biologics pharmaceutical products and have expanded the thera- nomodulatory biologics with their relevant immune Biotechnology-derived peutic options available
    [Show full text]
  • Bringing a Trait‐Based Approach to Plant‐Associated Fungi
    Biol. Rev. (2020), 95, pp. 409–433. 409 doi: 10.1111/brv.12570 Fungal functional ecology: bringing a trait-based approach to plant-associated fungi Amy E. Zanne1,∗ , Kessy Abarenkov2, Michelle E. Afkhami3, Carlos A. Aguilar-Trigueros4, Scott Bates5, Jennifer M. Bhatnagar6, Posy E. Busby7, Natalie Christian8,9, William K. Cornwell10, Thomas W. Crowther11, Habacuc Flores-Moreno12, Dimitrios Floudas13, Romina Gazis14, David Hibbett15, Peter Kennedy16, Daniel L. Lindner17, Daniel S. Maynard11, Amy M. Milo1, Rolf Henrik Nilsson18, Jeff Powell19, Mark Schildhauer20, Jonathan Schilling16 and Kathleen K. Treseder21 1Department of Biological Sciences, George Washington University, Washington, DC 20052, U.S.A. 2Natural History Museum, University of Tartu, Vanemuise 46, Tartu 51014, Estonia 3Department of Biology, University of Miami, Coral Gables, FL 33146, U.S.A. 4Freie Universit¨at-Berlin, Berlin-Brandenburg Institute of Advanced Biodiversity Research, 14195 Berlin, Germany 5Department of Biological Sciences, Purdue University Northwest, Westville, IN 46391, U.S.A. 6Department of Biology, Boston University, Boston, MA 02215, U.S.A. 7Department of Botany and Plant Pathology, Oregon State University, Corvallis, OR 97330, U.S.A. 8Department of Plant Biology, University of Illinois Urbana-Champaign, Urbana, IL 61801, U.S.A. 9Department of Biology, University of Louisville, Louisville, KY 40208, U.S.A. 10Evolution & Ecology Research Centre, School of Biological Earth and Environmental Sciences, University of New South Wales, Sydney, New South Wales 2052, Australia 11Department of Environmental Systems Science, Institute of Integrative Biology, ETH Z¨urich, 8092, Z¨urich, Switzerland 12Department of Ecology, Evolution, and Behavior, and Department of Forest Resources, University of Minnesota, St. Paul, MN 55108, U.S.A.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • This Thesis Has Been Submitted in Fulfilment of the Requirements for a Postgraduate Degree (E.G
    This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: • This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. • A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. • This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. • The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. • When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. Bio-Oligomers as Antibacterial Agents and Strategies for Bacterial Detection Jagath C. Kasturiarachchi Ph.D. The University of Edinburgh College of Medicine & Veterinary Medicine 2014 i Declaration This thesis represents my own work. All of the experiments described herein were performed by me. I received technical assistance to perform flow cytometry and confocal analysis as declared in the acknowledgements. All chemical .entities were synthesised by the Department of Chemistry at University of Edinburgh. …………………………………………. J C Kasturiarachchi ii Acknowledgements I am very grateful to Dr Kev Dhaliwal, Professor Mark Bradley and Professor Chris Haslett for their supervision and support. I would like to thank Dr Jeff Walton and Dr Nicos Avlonitis designing and synthesis of peptoid library. I would like to thank Dr Nicos Avlonitis, Dr Marc Vendrell and Miss Alize Marangoz for their support for the synthesis of peptide probes.
    [Show full text]
  • The Nuremberg Code Subverts Human Health and Safety by Requiring Animal Modeling
    UC San Diego UC San Diego Previously Published Works Title The Nuremberg Code subverts human health and safety by requiring animal modeling Permalink https://escholarship.org/uc/item/2947x3sq Journal BMC Medical Ethics, 13(1) ISSN 1472-6939 Authors Greek, Ray Pippus, Annalea Hansen, Lawrence A Publication Date 2012-07-08 DOI http://dx.doi.org/10.1186/1472-6939-13-16 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Greek et al. BMC Medical Ethics 2012, 13:16 http://www.biomedcentral.com/1472-6939/13/16 DEBATE Open Access The Nuremberg Code subverts human health and safety by requiring animal modeling Ray Greek1*, Annalea Pippus1 and Lawrence A Hansen2 Abstract Background: The requirement that animals be used in research and testing in order to protect humans was formalized in the Nuremberg Code and subsequent national and international laws, codes, and declarations. Discussion: We review the history of these requirements and contrast what was known via science about animal models then with what is known now. We further analyze the predictive value of animal models when used as test subjects for human response to drugs and disease. We explore the use of animals for models in toxicity testing as an example of the problem with using animal models. Summary: We conclude that the requirements for animal testing found in the Nuremberg Code were based on scientifically outdated principles, compromised by people with a vested interest in animal experimentation, serve no useful function, increase the cost of drug development, and prevent otherwise safe and efficacious drugs and therapies from being implemented.
    [Show full text]
  • Pharmacokinetics and Bioavailability of the Gnrh Analogs in the Form of Solution and Zn2+-Suspension After Single Subcutaneous Injection in Female Rats
    Eur J Drug Metab Pharmacokinet (2017) 42:251–259 DOI 10.1007/s13318-016-0342-5 ORIGINAL RESEARCH ARTICLE Pharmacokinetics and Bioavailability of the GnRH Analogs in the Form of Solution and Zn2+-Suspension After Single Subcutaneous Injection in Female Rats 1 2 3 Aleksandra Suszka-S´witek • Florian Ryszka • Barbara Dolin´ska • 4 5 1 1 Renata Dec • Alojzy Danch • Łukasz Filipczyk • Ryszard Wiaderkiewicz Published online: 14 May 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Follicle-stimulating hormone (FSH) and 17b-estradiol in the Background and Objectives Although many synthetic serum was measured by radioimmunological method. gonadoliberin analogs have been developed, only a few of Results The Extent of Biological Availability (EBA), calcu- them, including buserelin, were introduced into clinical lated on the base of AUC0-?, showed that in the form of practice. Dalarelin, which differs from buserelin by just solution buserelin and dalarelin display, respectively, only 13 one aminoacid in the position 6 (D-Ala), is not widely used and 8 % of biological availability of their suspension coun- so far. Gonadotropin-releasing hormone (GnRH) analogs terparts. Comparing both analogs, the EBA of dalarelin was are used to treat many different illnesses and are available half (53 %) that of buserelin delivered in the form of solution in different forms like solution for injection, nasal spray, and 83 % when they were delivered in the form of suspension. microspheres, etc. Unfortunately, none of the above drug The injection of buserelin or dalarelin, in the form of solution formulations can release the hormones for 24 h.
    [Show full text]
  • Half 1 3:50PM — 4:50PM in Vivo and in Vitro Activities of Auranofin Against Vancomycin-Resistant Enterococci
    Half 1 3:50PM — 4:50PM In vivo and in vitro activities of auranofin against vancomycin-resistant enterococci 1 1 1 Nader S. Abutaleb ,​ Marwa Alhashimi ​ , Ahmed Elkashif ​ , and Mohamed N. ​ ​ ​ Seleem1 ​ 1 Department​ of Comparative Pathobiology, Purdue University, WL, IN, 47905, US Vancomycin-resistant enterococci (VRE) are the second-most common cause of nosocomial infections causing more than 5% of all deaths attributed to antibiotic-resistant infections in USA. VRE acquired resistance to all antibiotics used for treatment, severely limiting the number of available effective therapeutic options. Consequently, novel antimicrobials are urgently needed. However, new antimicrobials are becoming difficult to develop. Repurposing FDA-approved drugs, with well-characterized toxicology and pharmacology, to find new applications outside the scope of their original medical indication is a novel way to reduce time and cost associated with antimicrobial innovation. In an intensive search for antimicrobial activity among FDA approved drugs, we identified auranofin as a potent drug against VRE. It demonstrated a potent activity against 30 clinical drug-resistant VRE isolates with MIC90(1μg/mL) Additionally, no enterococci resistant mutants could be developed against auranofin after 14 passages. It also, inhibited highly resistant stationary phase cells, biofilm formation on urinary catheters, protease, lipase and haemagglutinins production at sub-inhibitory concentrations. The promising features and the potent antimicrobial activity of auranofin prompted us to evaluate its in vivo efficacy against drug-of-choice, linezolid, in our established lethal VRE septicemia mouse model. Both drugs protected 100% of mice against a lethal VRE dose. However, auranofin was superior to linezolid in reducing the bacterial load in internal organs (liver, kidney and spleen).
    [Show full text]
  • SARS-Cov-2) Papain-Like Proteinase(Plpro
    JOURNAL OF VIROLOGY, Oct. 2010, p. 10063–10073 Vol. 84, No. 19 0022-538X/10/$12.00 doi:10.1128/JVI.00898-10 Copyright © 2010, American Society for Microbiology. All Rights Reserved. Papain-Like Protease 1 from Transmissible Gastroenteritis Virus: Crystal Structure and Enzymatic Activity toward Viral and Cellular Substratesᰔ Justyna A. Wojdyla,1† Ioannis Manolaridis,1‡ Puck B. van Kasteren,2 Marjolein Kikkert,2 Eric J. Snijder,2 Alexander E. Gorbalenya,2 and Paul A. Tucker1* EMBL Hamburg Outstation, c/o DESY, Notkestrasse 85, D-22603 Hamburg, Germany,1 and Molecular Virology Laboratory, Department of Medical Microbiology, Center of Infectious Diseases, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, Netherlands2 Received 27 April 2010/Accepted 15 July 2010 Coronaviruses encode two classes of cysteine proteases, which have narrow substrate specificities and either a chymotrypsin- or papain-like fold. These enzymes mediate the processing of the two precursor polyproteins of the viral replicase and are also thought to modulate host cell functions to facilitate infection. The papain-like protease 1 (PL1pro) domain is present in nonstructural protein 3 (nsp3) of alphacoronaviruses and subgroup 2a betacoronaviruses. It participates in the proteolytic processing of the N-terminal region of the replicase polyproteins in a manner that varies among different coronaviruses and remains poorly understood. Here we report the first structural and biochemical characterization of a purified coronavirus PL1pro domain, that of transmissible gastroenteritis virus (TGEV). Its tertiary structure is compared with that of severe acute respiratory syndrome (SARS) coronavirus PL2pro, a downstream paralog that is conserved in the nsp3’s of all coronaviruses.
    [Show full text]
  • Biomolecules-10-01137-V2.Pdf
    biomolecules Review Viral Ubiquitin and Ubiquitin-Like Deconjugases—Swiss Army Knives for Infection Maria Grazia Masucci Department of Cell and Molecular Biology, Karolinska Institutet, S-17177 Stockholm, Sweden; [email protected] Received: 13 July 2020; Accepted: 31 July 2020; Published: 1 August 2020 Abstract: Posttranslational modifications of cellular proteins by covalent conjugation of ubiquitin and ubiquitin-like polypeptides regulate numerous cellular processes that are captured by viruses to promote infection, replication, and spreading. The importance of these protein modifications for the viral life cycle is underscored by the discovery that many viruses encode deconjugases that reverse their functions. The structural and functional characterization of these viral enzymes and the identification of their viral and cellular substrates is providing valuable insights into the biology of viral infections and the host’s antiviral defense. Given the growing body of evidence demonstrating their key contribution to pathogenesis, the viral deconjugases are now recognized as attractive targets for the design of novel antiviral therapeutics. Keywords: ubiquitin-like deconjugase; herpesvirus; coronavirus; virus cycle; innate immunity; type I IFN 1. UbL Signaling Networks Viruses have shaped the fate of human societies throughout history. Understanding how these potentially life-threatening pathogens establish infection and how they interact with their hosts is our best strategy for acquiring the means to control the diseases they cause. Being obligatory intracellular parasites, viruses face a double challenge. On one side, they need to commandeer the molecular machinery of the host cell to support the production of new virus particles, while on the other side, they must hold back the multifaceted cellular and organismal defenses that are triggered by infection.
    [Show full text]
  • A Structure-Based Approach for Detection of Thiol Oxidoreductases and Their Catalytic Redox-Active Cysteine Residues
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Vadim Gladyshev Publications Biochemistry, Department of 2009 A Structure-Based Approach for Detection of Thiol Oxidoreductases and Their Catalytic Redox-Active Cysteine Residues Stefano M. Marino University of Nebraska-Lincoln, [email protected] Vadim N. Gladyshev University of Nebraska-Lincoln, [email protected] Follow this and additional works at: https://digitalcommons.unl.edu/biochemgladyshev Part of the Biochemistry, Biophysics, and Structural Biology Commons Marino, Stefano M. and Gladyshev, Vadim N., "A Structure-Based Approach for Detection of Thiol Oxidoreductases and Their Catalytic Redox-Active Cysteine Residues" (2009). Vadim Gladyshev Publications. 100. https://digitalcommons.unl.edu/biochemgladyshev/100 This Article is brought to you for free and open access by the Biochemistry, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Vadim Gladyshev Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. A Structure-Based Approach for Detection of Thiol Oxidoreductases and Their Catalytic Redox-Active Cysteine Residues Stefano M. Marino, Vadim N. Gladyshev* Department of Biochemistry and Redox Biology Center, University of Nebraska, Lincoln, Nebraska, United States of America Abstract Cysteine (Cys) residues often play critical roles in proteins, for example, in the formation of structural disulfide bonds, metal binding, targeting proteins to the membranes, and various catalytic functions. However, the structural determinants for various Cys functions are not clear. Thiol oxidoreductases, which are enzymes containing catalytic redox-active Cys residues, have been extensively studied, but even for these proteins there is little understanding of what distinguishes their catalytic redox Cys from other Cys functions.
    [Show full text]
  • Proteolytic Enzymes in Grass Pollen and Their Relationship to Allergenic Proteins
    Proteolytic Enzymes in Grass Pollen and their Relationship to Allergenic Proteins By Rohit G. Saldanha A thesis submitted in fulfilment of the requirements for the degree of Masters by Research Faculty of Medicine The University of New South Wales March 2005 TABLE OF CONTENTS TABLE OF CONTENTS 1 LIST OF FIGURES 6 LIST OF TABLES 8 LIST OF TABLES 8 ABBREVIATIONS 8 ACKNOWLEDGEMENTS 11 PUBLISHED WORK FROM THIS THESIS 12 ABSTRACT 13 1. ASTHMA AND SENSITISATION IN ALLERGIC DISEASES 14 1.1 Defining Asthma and its Clinical Presentation 14 1.2 Inflammatory Responses in Asthma 15 1.2.1 The Early Phase Response 15 1.2.2 The Late Phase Reaction 16 1.3 Effects of Airway Inflammation 16 1.3.1 Respiratory Epithelium 16 1.3.2 Airway Remodelling 17 1.4 Classification of Asthma 18 1.4.1 Extrinsic Asthma 19 1.4.2 Intrinsic Asthma 19 1.5 Prevalence of Asthma 20 1.6 Immunological Sensitisation 22 1.7 Antigen Presentation and development of T cell Responses. 22 1.8 Factors Influencing T cell Activation Responses 25 1.8.1 Co-Stimulatory Interactions 25 1.8.2 Cognate Cellular Interactions 26 1.8.3 Soluble Pro-inflammatory Factors 26 1.9 Intracellular Signalling Mechanisms Regulating T cell Differentiation 30 2 POLLEN ALLERGENS AND THEIR RELATIONSHIP TO PROTEOLYTIC ENZYMES 33 1 2.1 The Role of Pollen Allergens in Asthma 33 2.2 Environmental Factors influencing Pollen Exposure 33 2.3 Classification of Pollen Sources 35 2.3.1 Taxonomy of Pollen Sources 35 2.3.2 Cross-Reactivity between different Pollen Allergens 40 2.4 Classification of Pollen Allergens 41 2.4.1
    [Show full text]